TACT (Thermally Activated Combination Therapy)
Oncology (Solid Tumors with combination therapeutics)
Pre-clinicalActive
Key Facts
Indication
Oncology (Solid Tumors with combination therapeutics)
Phase
Pre-clinical
Status
Active
Company
About Theromics
Theromics is pioneering a protein-based nanopolymer platform that acts as a thermal accelerant for soft tissue ablation and targeted drug delivery. Its core technology addresses key limitations in current ablation techniques, such as heat-sink effects and irregular ablation zones, aiming to reduce the 30% recurrence rate. The platform also enables Thermally Activated Combination Therapy (TACT), which localizes therapeutics to minimize systemic side effects. The company is initially targeting applications in oncology and women's health, specifically uterine fibroids.
View full company profile